2025-09-09 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided, presented in a report format:

## Johnson & Johnson (JNJ) Analysis

**Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 30.16%
*   **VOO Cumulative Return:** 101.31%
*   **Absolute Divergence:** -71.1%
*   **Relative Divergence:** 11.6% (This indicates JNJ's performance is in the lower range of its historical divergence from the S&P 500.)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined. The relative divergence suggests that this underperformance is near the lower end of its historical range, indicating that the stock's underperformance relative to the S&P 500 is not unprecedented but still substantial.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
| :----------- | :------ | :------ | :------ | :---- | :------- |
| 2015-2017  | 28.0%   | 56.1%   | -1.0%   | -0.0  | 335.9  |
| 2016-2018  | 8.0%    | 56.6%   | -10.0%  | 0.0   | 310.3  |
| 2017-2019  | 18.0%   | 56.6%   | -12.0%  | 0.7   | 350.7  |
| 2018-2020  | 12.0%   | 59.2%   | -8.0%   | 0.3   | 378.4  |
| 2019-2021  | 32.0%   | 59.6%   | -16.0%  | 0.2   | 411.3  |
| 2020-2022  | 7.0%    | 61.4%   | 5.0%    | 0.2   | 424.7  |
| 2021-2023  | -15.0%  | 61.4%   | -33.0%  | 0.4   | 376.9  |
| 2022-2024  | -35.0%  | 61.4%   | -61.0%  | 0.3   | 347.7  |
| 2023-2025  | 3.0%    | 70.1%   | -50.0%  | 0.2   | 429.0  |

**Analysis:**

*   **CAGR:** Fluctuates significantly, showing inconsistent growth over different periods. Recent periods (2021-2025) show weaker performance.
*   **MDD:** High Maximum Drawdown values indicate significant potential for loss during downturns.
*   **Alpha:** Consistently negative alpha suggests underperformance relative to its benchmark, except for a brief period in 2020-2022.
*   **Beta:** Low Beta values (close to 0) indicate that JNJ's price is not very sensitive to the overall market movements.
*   **Cap(B):** Market Cap increases over time, peaking recently, indicating overall growth in the company's value.

### 2. Recent Stock Price Movement

*   **Current Price:** 178.43
*   **Last Market Data:** `{'price': 178.13, 'previousClose': 178.43, 'change': -0.17}`
*   **5-Day Moving Average:** 177.86
*   **20-Day Moving Average:** 176.66
*   **60-Day Moving Average:** 165.55

**Analysis:** The current price is above the 5-day, 20-day, and 60-day moving averages, indicating a recent upward trend. The slight decrease in the last market is negligible.

### 3. Technical Indicators & Outlook

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 57.49 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.28 (Slightly below zero, suggesting a potential weakening of the upward trend)
*   **Hybrid Signal:** cash_67%_Sell 4.0% of holdings (13 shares - Caution - MRI:0.34)
*   **20-Day Relative Divergence Change:** 1.9 (+) (Short-term increase, indicating recent outperformance relative to its benchmark)
*   **Expected Return:** -244.4% (Indicates significantly negative expected return compared to S&P 500 over the long term, suggesting caution for long-term investment)

**Analysis:** The MRI indicates low market risk. The neutral RSI suggests no immediate overbought or oversold conditions. The Hybrid signal advises caution, recommending a high cash position and selling a small portion of holdings. The recent increase in relative divergence is a positive short-term signal, but the extremely negative expected return is a strong concern for long-term investors.

### 4. Recent News & Significant Events

*   **Participation in Bernstein 2nd Annual Healthcare Forum:** Potential for investor updates and strategic insights.
*   **New Class of Sleep Drugs:** Indicates innovation in the pharmaceutical sector, which JNJ may be involved in or affected by.
*   **J&J vs. AbbVie Comparison:** Highlights JNJ's competitive position within the healthcare industry.
*   **Ronovo Surgical Investment:** J&J's venture arm's investment in Ronovo Surgical suggests a focus on surgical technology and growth opportunities.

**Analysis:** The news suggests JNJ is actively involved in industry events, facing competition, and investing in future growth areas.

### 4-2 Analyst Opinions

*   **Consensus:** Buy (~2.25)
*   **Opinions:** 23 analysts
*   **Target Price:** 177.47 (Average) / 200.00 (High) / 155.00 (Low)
*   **Recent Rating Changes:** No significant changes (→ )

**Analysis:** The analyst consensus is generally positive ("Buy"), with the average target price slightly below the current price. The range of target prices indicates some uncertainty among analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출         |
| :--------- | :----- | :----------- |
| 2025-07-24 | 2.3    | 23.74 B$     |
| 2025-04-23 | 4.57   | 21.89 B$     |
| 2024-10-23 | 1.12   | 22.47 B$     |
| 2024-07-25 | 1.95   | 22.45 B$     |
| 2025-07-24 | 1.95   | 22.45 B$     |

**Analysis:** Earnings per share (EPS) and revenue have fluctuated over the past few quarters. The most recent quarter shows an improvement in revenue, but the EPS is relatively low.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-06-30 | \$23.74B | 67.87%        |
| 2025-03-31 | \$21.89B | 66.40%        |
| 2024-12-31 | \$22.52B | 68.35%        |
| 2024-09-30 | \$22.47B | 69.01%        |
| 2024-06-30 | \$22.45B | 69.40%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
| :--------- | :-------- | :------- |
| 2025-06-30 | \$78.47B | 7.06%    |
| 2025-03-31 | \$78.11B | 14.08%   |
| 2024-12-31 | \$71.49B | 4.80%    |
| 2024-09-30 | \$70.16B | 3.84%    |
| 2024-06-30 | \$71.54B | 6.55%    |

**Analysis:**

*   **Revenue:** Revenue has shown some variability, with a recent increase.
*   **Profit Margin:** Profit margins are consistently high, indicating strong profitability.
*   **Equity:** Equity has generally increased, reflecting growth in the company's net assets.
*   **ROE:** Return on Equity (ROE) fluctuates, suggesting variability in the company's ability to generate profit from shareholders' investments.

### 7. Overall Summary

Johnson & Johnson (JNJ) exhibits a mixed outlook. While the company maintains strong profitability and is involved in strategic industry events, its recent performance has significantly lagged behind the S&P 500. Technical indicators suggest a recent short-term upward trend, but the long-term expected return is concerning. Analyst opinions are generally positive, but there's some uncertainty in target prices.  The financial data shows high profit margins but fluctuating revenue and ROE.

**Recommendation:** Given the underperformance relative to the market, the negative expected return, and the cautionary Hybrid Signal, a cautious approach is warranted. Investors should carefully consider their risk tolerance and investment horizon before making any decisions regarding JNJ. Monitoring future earnings and strategic developments will be crucial to reassessing the company's outlook.
